News for Instil Bio, Inc. (TIL)

Instil Bio shifts to bispecific immunotherapy with SYN-2510 for solid tumors.

**media[514491]**

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.

Instil Bio (TIL) reported Q3 2024 GAAP EPS of -$3.54.

**media[464680]**

Overview of the Recent Transaction On August 6, 2022, Curative Ventures V LLC (Trades, Portfolio) executed a significant transaction involving the sale of 1,898

Overview of BOXER CAPITAL's Recent Investment On September 18, 2024, BOXER CAPITAL, LLC (Trades, Portfolio) marked a significant portfolio addition by purchasin

Overview of Recent Transaction by Perceptive Advisors LLC On September 17, 2024, Perceptive Advisors LLC made a significant new investment in the biotechnology

U.S. stock futures were higher this morning, with the Dow futures gaining over 1% on Thursday. Shares of Steelcase Inc. SCS fell sharply in today's pre-market ...

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday. The Dow traded up 0.29% to 41,512.19 while the NASDAQ f...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. Shares of iTeos Therapeutics, Inc. ITOS fell sharply in t...

Market Rebound The stock market rebounded following last week's significant declines. Buy-the-dip interest supported the market, and upside momentum acted as a

Loading... Loading... Shares of ASP Isotopes Inc. ASPI fell during Friday's session after the company announced pricing of a $30 million public offering of 12 ...

China-based financial services business Sentage Holdings Inc. (SNTG) is up over 59 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.